| Members |
targetComponentId |
| Hydrocortisone 1% + Pramocaine 1% conventional release rectal foam |
Hydrocortisone and pramocaine only product |
| Hydrocortisone 1% + Pramocaine 1% foam enema |
Hydrocortisone and pramocaine only product |
| Hydrocortisone 100mg powder and solvent for injection solution vial |
Hydrocortisone (as hydrocortisone sodium succinate) 100 mg powder for solution for injection vial |
| Hydrocortisone 100mg/60mL |
Product containing precisely hydrocortisone 1.67 milligram/1 milliliter conventional release rectal suspension (clinical drug) |
| Hydrocortisone 100mg/60mL enema |
Product containing precisely hydrocortisone 1.67 milligram/1 milliliter conventional release rectal suspension (clinical drug) |
| Hydrocortisone 2% topical lotion |
Hydrocortisone acetate 20 mg/mL cutaneous lotion |
| Hydrocortisone acetate 1% eye drops |
Hydrocortisone 10 mg/mL eye solution |
| Hydrocortisone acetate 2.5% cream |
Product containing precisely hydrocortisone 25 milligram/1 milliliter conventional release cutaneous cream (clinical drug) |
| Hydrocortisone acetate+neomycin sulfate 1.5%/0.5% eye drops |
Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution |
| Hydrocortisone cypionate 10mg/5mL suspension |
Product containing precisely hydrocortisone 2 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Hydrocortisone/neomycin cream |
Hydrocortisone acetate 10 mg/g and neomycin sulfate 5 mg/g cutaneous cream |
| Hydrolyase |
Hydrolyase |
| Hydromorphone hydrochloride 100% powder |
Hydromorphone only product |
| Hydromorphone hydrochloride 12mg m/r capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
| Hydromorphone hydrochloride 12mg prolonged-release oral capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
| Hydromorphone hydrochloride 1mg/mL injection solution ampule |
Hydromorphone hydrochloride 1 mg/mL solution for injection |
| Hydromorphone hydrochloride 32mg m/r capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
| Hydromorphone hydrochloride 32mg prolonged-release oral capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
| Hydromorphone hydrochloride 4mg/mL injection solution ampule |
Hydromorphone hydrochloride 4 mg/mL solution for injection |
| Hydrotherapy NOS |
Hydrotherapy |
| Hydrotherapy NOS |
Hydrotherapy |
| Hydrous wool fat+zinc oxide 4/8% conventional release cutaneous cream |
Lanolin and zinc oxide only product in cutaneous dose form |
| Hydrous wool fat+zinc oxide 4/8% cream |
Lanolin and zinc oxide only product in cutaneous dose form |
| Hydroxocobalamin 1mg/mL injection 1mL ampule |
Product containing precisely hydroxocobalamin (as hydroxocobalamin acetate) 1 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Hydroxocobalamin 2.5g powder for conventional release solution for injection vial |
Product containing only hydroxocobalamin in parenteral dose form (medicinal product form) |
| Hydroxocobalamin 2.5g powder for injection solution vial + diluent |
Product containing only hydroxocobalamin in parenteral dose form (medicinal product form) |
| Hydroxyethylcellulose 0.44% conventional release eye drops |
Product containing only hyetellose (medicinal product) |
| Hydroxyethylcellulose 0.44% single-use eye drops |
Product containing only hyetellose (medicinal product) |
| Hydroxypropyl methylcellulose 0.32% conventional release eye drops |
Hypromellose 3.2 mg/mL eye solution |
| Hydroxypropyl methylcellulose 0.32% single-use eye drops |
Hypromellose 3.2 mg/mL eye solution |
| Hydroxypropylmethylcellulose 2% eye drops |
Product containing precisely hypromellose 2 milligram/1 milliliter conventional release eye solution (clinical drug) |
| Hymenoptera species |
Order Hymenoptera (organism) |
| Hyoscine butylbromide allergy |
Allergy to hyoscine |
| Hyoscine hydrobromide 0.125% eye drops |
Hyoscine (as hyoscine hydrobromide) 1.25 mg/mL eye solution |
| Hyoscine hydrobromide 0.25% eye drops |
Product containing precisely scopolamine (as scopolamine hydrobromide) 2.5 milligram/1 milliliter conventional release eye solution (clinical drug) |
| Hyoscine hydrobromide 0.5% eye drops |
Hyoscine (as hyoscine hydrobromide) 5 mg/mL eye solution |
| Hyoscine hydrobromide allergy |
Allergy to hyoscine |
| Hyoscyamine sulfate 0.031mg/1 mL |
Hyoscyamine only product |
| Hyoscyamine sulfate 0.125mg/5mL elixir |
Hyoscyamine sulfate 25 microgram/mL oral solution |
| Hyoscyamine sulfate 0.125mg/5mL liquid |
Hyoscyamine sulfate 25 microgram/mL oral solution |
| Hyoscyamine sulfate 0.125mg/mL liquid |
Hyoscyamine sulfate 25 microgram/mL oral solution |
| Hyperbetaglobulinemia |
Hyperbetaglobulinemia |
| Hypercalcemia caused by thiazide AND vitamin A |
Hypercalcemia caused by thiazide and/or retinol (disorder) |
| Hyperchromia |
Hyperchromatism |
| Hypercupremia |
Blood copper level above reference range |
| Hypercupremia |
Blood copper level above reference range |
| Hyperglobulinemia |
Hyperglobulinemia |
| Hyperglycemia clinical management plan |
Hyperglycemia clinical management plan |
| Hyperglycemia self management plan |
Hyperglycemia self management plan |
| Hyperhidrosis, premature cavities and premolar aplasia |
Book syndrome (disorder) |
| Hyperinsulinemia due to benign insulinoma |
Hyperinsulinemia due to malignant insulinoma |
| Hyperinsulinemia due to insulinoma |
Hyperinsulinemia due to malignant insulinoma |
| Hyperlipidaemia NOS |
Hyperlipidemia |
| Hyperlipidemia NOS |
Hyperlipidemia |
| Hyperlipidemia clinical management plan |
Hyperlipidaemia clinical management plan |
| Hyperpyrexia |
Hyperpyrexia (finding) |
| Hypersensitivity alveolitis in lungworm infection |
Hypersensitivity pneumonitis (disorder) |
| Hypersensitivity skin test NOS |
Hypersensitivity skin testing |
| Hypersensitivity skin test NOS |
Hypersensitivity skin testing |
| Hypersomnolence caused by substance |
Drug-induced hypersomnia |
| Hypertension clinical management plan |
Hypertension clinical management plan (record artifact) |
| Hypertension of pregnancy NOS |
Pregnancy-induced hypertension |
| Hypertension of pregnancy NOS |
Pregnancy-induced hypertension |
| Hypertensive disease NOS |
Hypertensive disorder, systemic arterial (disorder) |
| Hypertensive disease NOS |
Hypertensive disorder, systemic arterial (disorder) |
| Hypertensive ischemic ulcer |
Ischemic ulcer of skin due to arterial hypertension (disorder) |
| Hyperthermia in newborn, unspecified |
Neonatal hyperthermia |
| Hypertonic saline |
Sodium chloride only product |
| Hypertonic uterine inertia with antenatal problem |
Hypertonic uterine inertia |
| Hypertrichosis and acromegaloid facial appearance syndrome |
Cantu's syndrome |
| Hypertrichosis universalis |
Congenital hypertrichosis |
| Hypertrophic cardiomyopathy associated with another disorder |
Hypertrophic cardiomyopathy due to disorder |
| Hypertrophic cardiomyopathy secondary to Friedreich's ataxia |
Hypertrophic cardiomyopathy due to Friedreich ataxia |
| Hypertrophic cardiomyopathy secondary to hyperthyroidism |
Hypertrophic cardiomyopathy due to hyperthyroidism |
| Hypertrophic cardiomyopathy secondary to neuromuscular disorder |
Hypertrophic cardiomyopathy due to neuromuscular disorder |
| Hypertrophic glandular gastritis |
Hypertrophic gastritis |
| Hypertrophy of bone |
External hyperostosis |
| Hypertrophy of bone and cartilage |
External hyperostosis |
| Hypertrophy of cartilage |
Hypertrophy |
| Hypnotic |
Hypnotic agent (substance) |
| Hypnotic agent |
Hypnotic agent (substance) |
| Hypnotic dependence with current use |
Hypnotic dependence (disorder) |
| Hypnotic withdrawal syndrome without complication |
Hypnotic withdrawal |
| Hypoactive sexual desire disorder |
Lack or loss of sexual desire |
| Hypoalphaglobulinemia |
Hypoalphaglobulinaemia |
| Hypobetaglobulinemia |
Hypoalphaglobulinaemia |
| Hypoglobulinemia |
Hypoglobulinaemia |
| Hypoglycaemia unspecified |
Hypoglycaemia |
| Hypoglycemia clinical management plan |
Hypoglycemia clinical management plan (record artifact) |
| Hypoglycemia self management plan |
Hypoglycaemia self management plan |
| Hypoglycemia unspecified |
Hypoglycaemia |
| Hypoglycemia unspecified NOS |
Hypoglycaemia |
| Hypogonadism, diabetes mellitus, alopecia, mental retardation and electrocardiographic abnormalities |
Woodhouse Sakati syndrome |
| Hypopharyngeal TNM finding |
American Joint Committee on Cancer allowable value |
| Hypophysectomy by other specified approach |
Hypophysectomy |
| Hypospadias, balanic |
Glanular hypospadias |
| Hypospadias, hypertelorism, coloboma, deafness syndrome |
BSG syndrome |
| Hypotension NOS |
Low blood pressure |
| Hypotension NOS |
Low blood pressure |
| Hypotensive agent |
Hypotensive agent (substance) |
| Hypothyroidism clinical management plan |
Hypothyroidism clinical management plan |